The pharmaceutical industry could enjoy a secular tailwind propelled by the aging population.
The portfolio is filled with high-quality, wide-moat firms. Some 83% of the assets in this ETF are invested in companies with economic moats, which Morningstar's equity analysts define as competitive advantages.
Given litigation worries in the health-care sector, an ETF is an effective vehicle for diversifying away much of the company-specific risk. Read more